BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Letai AG. Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8(2):121–132. doi:10.1038/nrc2297
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060. doi:10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP. The tao of myeloma. Blood. 2014;124(12):1873–1879. doi:10.1182/blood-2014-05-578732
   PubMed Web of Science ®Google Scholar
• Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–1937. doi:10.1200/JCO.19.02515
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528. doi:10.1056/NEJMoa1714678
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115. doi:10.1056/NEJMoa1817249
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, Phase 3 study. Lancet. 2019;394(10192):29–38. doi:10.1016/S0140-6736(19)31240-1
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. doi:10.1182/blood.2020005288
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 Family reunion. Mol Cell. 2010;37(3):299–310. doi:10.1016/j.molcel.2010.01.025
   PubMed Web of Science ®Google Scholar
• Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667–3683. doi:10.1038/emboj.2011.307
   PubMed Web of Science ®Google Scholar
• Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018;25(1):46–55. doi:10.1038/cdd.2017.179
   PubMed Web of Science ®Google Scholar
• Carrington EM, Vikstrom IB, Light A, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci U S A. 2010;107(24):10967–10971. doi:10.1073/pnas.1005256107
   Web of Science ®Google Scholar
• Gaudette BT, Iwakoshi NN, Boise LH. Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation. J Biol Chem. 2014;289(34):23629–23640. doi:10.1074/jbc.M114.569376
   Web of Science ®Google Scholar
• Peperzak V, Vikstrom I, Walker J, et al. Mcl-1 is essential for the survival of plasma cells. Nat Immunol. 2013;14(3):290–297. doi:10.1038/ni.2527
   Web of Science ®Google Scholar
• Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 1998;58(2):256–262.
   Web of Science ®Google Scholar
• Puthier D, Pellat-Deceunynck C, Barillé S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia. 1999;13(2):289–294. doi:10.1038/sj.leu.2401302
   Web of Science ®Google Scholar
• Wuillème-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248–1252. doi:10.1038/sj.leu.2403784
   PubMed Web of Science ®Google Scholar
• Gupta VA, Matulis SM, Conage-Pough JE, et al. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood. 2017;129(14):1969–1979. doi:10.1182/blood-2016-10-745059
   PubMed Web of Science ®Google Scholar
• Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29(12):3945–3950. doi:10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O
   Web of Science ®Google Scholar
• Puthier D, Derenne S, Barille S, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol. 1999;107(2):392–395. doi:10.1046/j.1365-2141.1999.01705.x
   Web of Science ®Google Scholar
• Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ. 2000;7(12):1244–1252. doi:10.1038/sj.cdd.4400758
   PubMed Web of Science ®Google Scholar
• Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene. 2003;22(19):2950–2959. doi:10.1038/sj.onc.1206423
   Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105–115. doi:10.1016/S1074-7613(00)80011-4
   PubMed Web of Science ®Google Scholar
• Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332(6159):83–85. doi:10.1038/332083a0
   PubMed Web of Science ®Google Scholar
• Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194–199. doi:10.1182/blood.V100.1.194
   PubMed Web of Science ®Google Scholar
• Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885–1893. doi:10.1182/blood.V99.6.1885
   PubMed Web of Science ®Google Scholar
• Gong J-N, Khong T, Segal D, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128(14):1834. doi:10.1182/blood-2016-03-704908
   PubMed Web of Science ®Google Scholar
• Morales AA, Kurtoglu M, Matulis SM, et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118(5):1329–1339. doi:10.1182/blood-2011-01-327197
   PubMed Web of Science ®Google Scholar
• Soderquist S, Eastman A. BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol Cancer Ther. 2016;15(9):2011. doi:10.1158/1535-7163.MCT-16-0031
   PubMed Web of Science ®Google Scholar
• Albershardt TC, Salerni BL, Soderquist RS, et al. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem. 2011;286(28):24882–24895. doi:10.1074/jbc.M111.255828
   PubMed Web of Science ®Google Scholar
• Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ. 2020;27(3):999–1007. doi:10.1038/s41418-019-0391-9
   Web of Science ®Google Scholar
• Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009;16(7):1030–1039. doi:10.1038/cdd.2009.48
   PubMed Web of Science ®Google Scholar
• van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–399. doi:10.1016/j.ccr.2006.08.027
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681. doi:10.1038/nature03579
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–496. doi:10.1200/JCO.2011.34.7898
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Matulis SM, Gupta VA, Nooka AK, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016;30(5):1086–1093. doi:10.1038/leu.2015.350
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210–212. doi:10.1038/leu.2013.216
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26(16):2374–2380. doi:10.1038/sj.onc.1210028
   PubMed Web of Science ®Google Scholar
• Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia. 2007;21(7):1549–1560. doi:10.1038/sj.leu.2404719
   Web of Science ®Google Scholar
• Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007;13(2 Pt 1):621–629. doi:10.1158/1078-0432.CCR-06-1526
   PubMed Web of Science ®Google Scholar
• Dousset C, Maiga S, Gomez-Bougie P, et al. BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. Br J Haematol. 2017;179(4):684–688.
   Web of Science ®Google Scholar
• Bajpai R, Matulis SM, Wei C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. 2016;35(30):3955–3964. doi:10.1038/onc.2015.464
   Web of Science ®Google Scholar
• Bajpai R, Sharma A, Achreja A, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020;11(1):1228. doi:10.1038/s41467-020-15051-z
   Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118(14):3901–3910. doi:10.1182/blood-2010-11-317438
   PubMed Web of Science ®Google Scholar
• Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132–1144. doi:10.1158/1535-7163.MCT-15-0730
   PubMed Web of Science ®Google Scholar
• Touzeau C, Ryan J, Guerriero J, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30(3):761–764. doi:10.1038/leu.2015.184
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Maiga S, Tessoulin B, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018;132(25):2656–2669. doi:10.1182/blood-2018-03-836718
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409. doi:10.1182/blood-2017-06-788786
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa1513257
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol. 2020;In press.
   Google Scholar
• Maples KT, Nooka AK, Gupta V, et al. Natural history of multiple myeloma patients refractory to venetoclax: a single center experience. Am J Hematol. 2020;96(3):E68–E71. doi:10.1002/ajh.26064
   Web of Science ®Google Scholar
• Mateos M-V, Moreau P, Dimopoulos MA, et al. A Phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. J Clin Oncol. 2020;38(15_suppl):TPS8554–TPS8554. doi:10.1200/JCO.2020.38.15_suppl.TPS8554
   Web of Science ®Google Scholar
• Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65(14):6282–6293. doi:10.1158/0008-5472.CAN-05-0676
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–2400. doi:10.1182/blood-2017-06-788323
   PubMed Web of Science ®Google Scholar
• Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–1642. doi:10.1016/S1470-2045(20)30525-8
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Baz RC, Harrison SJ, et al. Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, ± bortezomib, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2020;38(15_suppl):8511. doi:10.1200/JCO.2020.38.15_suppl.8511
   Web of Science ®Google Scholar
• Costa LJ, Burwick N, Jakubowiak A, et al. Assessment of minimal residual disease by next-generation sequencing and fluorodeoxyglucose-positron emission tomography in patients with relapsed/refractory multiple myeloma treated with venetoclax in combination with carfilzomib and dexamethasone. Blood. 2020;136(Supplement 1):4–5. doi:10.1182/blood-2020-134737
   Web of Science ®Google Scholar
• Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124(7):1047–1055. doi:10.1182/blood-2014-01-548941
   PubMed Web of Science ®Google Scholar
• Huang X, Sun Y, Trow P, et al. Patient subgroup identification for clinical drug development. Stat Med. 2017;36(9):1414–1428. doi:10.1002/sim.7236
   PubMed Web of Science ®Google Scholar
• Certo M, Moore VDG, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–365. doi:10.1016/j.ccr.2006.03.027
   PubMed Web of Science ®Google Scholar
• Matulis SM, Gupta VA, Neri P, et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia. 2019;33(5):1291–1296. doi:10.1038/s41375-018-0374-8
   PubMed Web of Science ®Google Scholar
• Neri P, Maity R, Alberge J-B, et al. Mutations and copy number gains of the BCL2 family members mediate resistance to venetoclax in multiple myeloma (MM) patients. Blood. 2019;134(Supplement_1):572. doi:10.1182/blood-2019-127593
   Web of Science ®Google Scholar
• Birkinshaw RW, Gong JN, Luo CS, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun. 2019;10(1):2385. doi:10.1038/s41467-019-10363-1
   PubMed Web of Science ®Google Scholar
• Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):e434–e437. doi:10.3324/haematol.2019.222588
   PubMed Web of Science ®Google Scholar
• Blombery P, Thompson ER, Nguyen T, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020;135(10):773–777. doi:10.1182/blood.2019004205
   PubMed Web of Science ®Google Scholar
• Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8(12):1582–1597. doi:10.1158/2159-8290.CD-18-0387
   PubMed Web of Science ®Google Scholar
• Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–482. doi:10.1038/nature19830
   PubMed Web of Science ®Google Scholar
• Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341. doi:10.1038/s41467-018-07551-w
   PubMed Web of Science ®Google Scholar
• Szlavik Z, Csekei M, Paczal A, et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J Med Chem. 2020;63(22):13762–13795. doi:10.1021/acs.jmedchem.0c01234
   PubMed Web of Science ®Google Scholar
• Caenepeel S, Karen R, Belmontes B, et al. Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 2020;80(16 Supplement):6218.
   Web of Science ®Google Scholar
• Brennan MS, Chang C, Tai L, et al. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018;132(15):1573–1583. doi:10.1182/blood-2018-06-859405
   PubMed Web of Science ®Google Scholar
• Thomas RL, Roberts DJ, Kubli DA, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27(12):1365–1377.
   PubMed Web of Science ®Google Scholar
• Wang X, Bathina M, Lynch J, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27(12):1351–1364. doi:10.1101/gad.215855.113
   PubMed Web of Science ®Google Scholar
• Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 2019;3(24):4202–4214. doi:10.1182/bloodadvances.2019000702
   PubMed Web of Science ®Google Scholar
• Seiller C, Maiga S, Touzeau C, et al. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. Cell Death Dis. 2020;11(5):316. doi:10.1038/s41419-020-2505-1
   Web of Science ®Google Scholar
• Siu KT, Huang C, Panaroni C, et al. BCL2 blockade overcomes MCL1 resistance in multiple myeloma. Leukemia. 2019;33(8):2098–2102. doi:10.1038/s41375-019-0421-0
   Web of Science ®Google Scholar
• Algarín EM, Díaz-Tejedor A, Mogollón P, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica. 2020;105(3):e116–e120. doi:10.3324/haematol.2018.212308
   Web of Science ®Google Scholar
• Wong KY, Chim CS. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol. 2020;72(5):728–737. doi:10.1111/jphp.13240
   Web of Science ®Google Scholar
• Tao ZF, Hasvold L, Wang L, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett. 2014;5(10):1088–1093. doi:10.1021/ml5001867
   PubMed Web of Science ®Google Scholar
• Wang L, Doherty GA, Judd AS, et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor. ACS Med Chem Lett. 2020;11(10):1829–1836. doi:10.1021/acsmedchemlett.9b00568
   PubMed Web of Science ®Google Scholar
• Leverson JD, Phillips DC, Mitten MJ, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra240. doi:10.1126/scitranslmed.aaa4642
   Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428. doi:10.1158/0008-5472.CAN-07-5836
   PubMed Web of Science ®Google Scholar
• Balachander SB, Criscione SW, Byth KF, et al. AZD4320, a dual inhibitor of Bcl-2 and Bcl-x(L), induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia. Clin Cancer Res. 2020;26(24):6535–6549. doi:10.1158/1078-0432.CCR-20-0863
   Web of Science ®Google Scholar
• Khan S, Zhang X, Lv D, et al. A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938–1947. doi:10.1038/s41591-019-0668-z
   PubMed Web of Science ®Google Scholar